These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 30501593)

  • 1. Recent Development of Transition Metal Complexes as Chemotherapeutic Hypoxia Activated Prodrug (HAP).
    Jagathesan K; Roy S
    ChemMedChem; 2024 Jul; 19(14):e202400127. PubMed ID: 38634306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metal-based carbon monoxide releasing molecules with promising cytotoxic properties.
    Mansour AM; Khaled RM; Ferraro G; Shehab OR; Merlino A
    Dalton Trans; 2024 Jun; 53(23):9612-9656. PubMed ID: 38808485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome P450-activated prodrugs.
    Ortiz de Montellano PR
    Future Med Chem; 2013 Feb; 5(2):213-28. PubMed ID: 23360144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation and Delivery of Tetrazine-Responsive Bioorthogonal Prodrugs.
    Wang Y; Zhang C; Wu H; Feng P
    Molecules; 2020 Nov; 25(23):. PubMed ID: 33266075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physicochemical Considerations of Tumor Selective Drug Delivery and Activity Confinement with Particular Reference to 1,2-Bis(Sulfonyl)-1- Alkylhydrazines Delivery.
    Penketh P; Williamson H; Shyam K
    Curr Drug Deliv; 2020; 17(5):362-374. PubMed ID: 32342817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour endoproteases: the cutting edge of cancer drug delivery?
    Atkinson JM; Siller CS; Gill JH
    Br J Pharmacol; 2008 Apr; 153(7):1344-52. PubMed ID: 18204490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular Activation of Anticancer Therapeutics Using Polymeric Bioorthogonal Nanocatalysts.
    Zhang X; Landis RF; Keshri P; Cao-Milán R; Luther DC; Gopalakrishnan S; Liu Y; Huang R; Li G; Malassiné M; Uddin I; Rondon B; Rotello VM
    Adv Healthc Mater; 2021 Mar; 10(5):e2001627. PubMed ID: 33314745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyprodrugs for tumor chemotherapy: from molecular structure to drug release performance.
    Liu P
    J Mater Chem B; 2023 Oct; 11(40):9565-9571. PubMed ID: 37791422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting drug delivery with light: A highly focused approach.
    Rapp TL; DeForest CA
    Adv Drug Deliv Rev; 2021 Apr; 171():94-107. PubMed ID: 33486009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years.
    Najjar A; Najjar A; Karaman R
    Molecules; 2020 Feb; 25(4):. PubMed ID: 32079289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transition Metal Ru(II) Catalysts Immobilized Nanoreactors for Conditional Bioorthogonal Catalysis in Cells.
    Gao Z; Li Y; Xing J; Lu Y; Shao Q; Hu J; Zhao S; He W; Sun B
    ACS Appl Mater Interfaces; 2024 Apr; 16(13):15870-15878. PubMed ID: 38520329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer platinum-based photo-oxidants in a new light.
    Vigueras G; Gasser G
    Nat Chem; 2023 Jul; 15(7):896-898. PubMed ID: 37407672
    [No Abstract]   [Full Text] [Related]  

  • 13. Harnessing External Irradiation for Precise Activation of Metal-Based Agents in Cancer Therapy.
    Wang Y; Meng L; Zhao F; Zhao L; Gao W; Yu Q; Chen P; Sun Y
    Chembiochem; 2024 Jun; ():e202400305. PubMed ID: 38825577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From the Discovery of Targets to Delivery Systems: How to Decipher and Improve the Metallodrugs' Actions at a Molecular Level.
    Iacobucci I; La Manna S; Cipollone I; Monaco V; Canè L; Cozzolino F
    Pharmaceutics; 2023 Jul; 15(7):. PubMed ID: 37514183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multitarget-Directed Gallium(III) Tris(acyl-pyrazolonate) Complexes Induce Ferroptosis in Cancer Cells via Dysregulation of Cell Redox Homeostasis and Inhibition of the Mevalonate Pathway.
    Romani D; Marchetti F; Di Nicola C; Cuccioloni M; Gong C; Eleuteri AM; Galindo A; Fadaei-Tirani F; Nabissi M; Pettinari R
    J Med Chem; 2023 Mar; 66(5):3212-3225. PubMed ID: 36802330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transition Metal-Based Prodrugs for Anticancer Drug Delivery.
    Phillips AMF; Pombeiro AJL
    Curr Med Chem; 2019; 26(41):7476-7519. PubMed ID: 30501593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer metallodrugs: where is the next cisplatin?
    Hanif M; Hartinger CG
    Future Med Chem; 2018 Mar; 10(6):615-617. PubMed ID: 29411994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redox activation of metal-based prodrugs as a strategy for drug delivery.
    Graf N; Lippard SJ
    Adv Drug Deliv Rev; 2012 Aug; 64(11):993-1004. PubMed ID: 22289471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Light-activated ruthenium (II)-bicalutamide prodrugs for prostate cancer.
    Zhao J; Liu N; Sun S; Gou S; Wang X; Wang Z; Li X; Zhang W
    J Inorg Biochem; 2019 Jul; 196():110684. PubMed ID: 31054419
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.